PARIS--(BUSINESS WIRE)--Regulatory News:
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2017 Registration Document.
The 2017 Registration Document, filed with the French Market Authorities (Autorité des Marchés Financiers) on April 25, 2018, is available to the public free of charge upon request, as per current legal regulations, at on the Company’s website: http://www.onxeo.com/en/investisseurs/resultats-et-publications/documents-de-reference.
Copies of the Registration Document are also available at the head offices of Onxeo – 49 Boulevard du Général Martial Valin, 75015 Paris.
The annual financial report, the report on corporate governance, as well as the auditors’ reports and information on the fees paid to the statutory auditors in 2017 are included in this Registration Document
About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today. The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).
Onxeo is also developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.
AsiDNA™ is the first compound generated from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON™ will continue to generate new compounds that will broaden Onxeo’s pipeline.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or
implicitly contains certain forward-looking statements concerning Onxeo
and its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Onxeo is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a
result of new information, future events or otherwise. For a discussion
of risks and uncertainties which could cause actual results, financial
condition, performance or achievements of Onxeo to differ from those
contained in the forward-looking statements, please refer to the section
5.5.1.4 “Risk Factors” ("Facteurs de Risque") of the 2016
reference document filed with the Autorité des marchés financiers
on April 24, 2017 under number D.17-0423, which is available on the Autorité
des marchés financiers website (www.amf-france.org)
or on the Company’s website (www.onxeo.com).
